Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.

Ophthalmology and eye diseases Pub Date : 2016-04-28 eCollection Date: 2016-01-01 DOI:10.4137/OED.S38028

Fernanda Pacella, Adriana Francesca Ferraresi, Paolo Turchetti, Tommaso Lenzi, Rosalia Giustolisi, Andrea Bottone, Valeria Fameli, Maria Rosaria Romano, Elena Pacella

{"title":"Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.","authors":"Fernanda Pacella, Adriana Francesca Ferraresi, Paolo Turchetti, Tommaso Lenzi, Rosalia Giustolisi, Andrea Bottone, Valeria Fameli, Maria Rosaria Romano, Elena Pacella","doi":"10.4137/OED.S38028","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME).Methods: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection.Results: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up.Conclusion: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"8 ","pages":"11-6"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/OED.S38028","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and eye diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/OED.S38028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 48

Abstract

Aim: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME).

Methods: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection.

Results: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up.

Conclusion: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

玻璃体内注射Ozurdex(®)植体治疗持续性糖尿病黄斑水肿患者，随访6个月。

目的:评价玻璃体内注射地塞米松治疗糖尿病性黄斑水肿(DME)的疗效。方法:对17例(19眼)持续性二甲醚患者玻璃体内置入700 μg缓释地塞米松植入体(Ozurdex®)。通过早期治疗糖尿病视网膜病变研究(ETDRS)评估最佳矫正视力(BCVA)。采用光谱域光学相干层析技术测量中央黄斑厚度(CMT)。在基线(T0)进行BCVA和CMT检查，并在注射后3天、1个月(T1)、3个月(T3)、4个月(T4)和6个月(T6)重复检查。结果:地塞米松植入物可改善注射后T1、T3、T4、T6时的ETDRS。CMT在T1、T3和T4时降低，而在T6时，CMT值与基线无统计学差异。随访期间无并发症发生。结论:我们的数据表明地塞米松植入物在6个月内有效减轻DME症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊